US FDA declines to approve Disc Medicine’s rare disease drug
On February 13, 2026, the U.S. Food and Drug Administration turned down the approval of Disc Medicine’s experimental treatment, sending the company’s stock tumbling 31.6% to $48.90. The drug, bitopertin, was being developed to help patients suffering from erythropoietic protoporphyria, a rare genetic metabolic disorder. Erythropoietic protoporphyria arises from a deficiency in the ferrochelatase enzyme, […]